Hummingbird Bioscience is on a mission to unravel the complexities of human disease and revolutionize treatment outcomes. We use systems biology to develop unparalleled insights into disease biology and apply computationally guided platforms to discover and engineer breakthrough biotherapeutics.

This is a bold, new way to find the right drugs for the right people

Novel, integrative approaches to disease biology
Recognition of the importance of both tumor evolution and evasion of immune response as as key “hallmark of cancer” has provided a wide new class of targets. Building on these insights, Hummingbird is developing a comprehensive framework to systematically address the barriers to an effective immune response in every patient.

Rational Antibody Discovery Platform
Our proprietary platform has the game-changing ability to identify critical functional regions of target proteins (epitopes) and isolate antibodies that bind them, allowing us to fully maximize the therapeutic potential of a target

Data and model driven translational medicine and biomarker identification
Mechanism driven -omics analysis informs selection of appropriate pre-clinical models, role of  tumor heterogeneity and down-stream biomarker development

Recent News

  • 25 July 2020 Hummingbird Bioscience Scientific Advisory Board member Prof. John Connolly appointed as Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy (Full Press Release - External Link
  • 11 May 2020 Hummingbird Bioscience closes US$25M investment with Series B extension (Full Press Release)
    • 20 February 2020 Hummingbird Bioscience announces agreement with Mycenax Biotech for production of anti-VISTA antibody HMBD-002 for cancer clinical trial (Full Press Release)
    • 8 January 2020 Hummingbird Bioscience publishes preclinical data demonstrating efficacy of HMBD-001 in HER3 driven cancers (Full Press Release)
    • 5 December 2019 Hummingbird Bioscience raises US$19 Million in Series B financing to support expansion of its discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics (Full Press Release)
    • 16 September 2019 Hummingbird Bioscience announces collaboration with Amgen to co-discover novel therapeutics using Hummingbird’s Rational Antibody Discovery Platform (Full Press Release)

    • 8 August 2019 Cancer Research UK and Hummingbird Bioscience join forces to advance novel antibody drug into clinical trials (Full Press Release)
    • 25 February 2019 Hummingbird Bioscience awarded $13.1 Million grant by the Cancer Prevention and Research Institute of Texas (CPRIT) (Full Press Release)

    • 18 February 2019 Hummingbird Bioscience announces Nobel Laureate Dr. James Allison and Dr. Padmanee Sharma join its Scientific Advisory Board (Full Press Release)